Category Archives: Cf

New York City FC beat Inter Miami CF 2-0 in the July heat on Saturday night at Yankee Stadium. Maxi Moralez and Hber scored to secure all three points, however that result is an afterthought on what will be remembered as the final game Taty Castellanos played in an NYCFC jersey.

While no official announcement has been made, every sign points to Taty leaving for Girona FC in La Liga. The fans and his teammates knew exactly what is going on: The night was dedicated to Taty. Fans held banners out thanking him and gave him a standing ovation when he was subbed off for Heber in the 61st minute. Every Taty touch piqued the crowds interest, and his chances evoked anticipatory cheers.

It was a bittersweet night for NYCFC fans as the performance was generally one to be proud of: This was a professional 2-0 win where the defense held firm and a second goal was scored to put the game to bed. No matter what kind of performance there was though, it was always going to be about Taty.

Game Stats

NYCFC: 18 shots, 6 on goal, 46.1% possession, 535 passes, 88% accuracy, 8 fouls

Inter Miami CF: 10 shots, 4 on goal, 53.9% possession, 632 passes, 88% accuracy, 7 fouls

The entire game Saturday night felt like it revolved around Taty. Every fan in attendance knew what made this game so special. This was not just an end-of-July game against lowly Inter Miami, it was an opportunity to show their love one final time for a club legend.

Fans displayed their appreciation multiple times throughout the game. There was a massive cheer during introductions, supporters unfurled a banner during the game, and he received a standing ovation as he was subbed off. Speaking of that substitution, interim head coach Nick Cushing said postgame that Taty was taken off due to being a little tired from the heat.

The only thing missing from Tatys final game for NYCFC was a goal. He put the ball in the back of the net in the 33rd minute but it was called offside. On replay, it appeared that Taty was behind the ball when it was played into him, which would make the call on the field incorrect, but VAR did not intervene. On the bright side, he notched an assist on Maxis goal.

After the game, Cushing did not confirm that Taty is leaving, but he did toss around some hypotheticals in order to address the reception Taty received from the crowd.

He deserves all of that if thats his last game, Im proud of our fans for the ovation. Hell remember that, Cushing said postgame.

All in all, Taty was sent off to Spain in a great way: Three points at home and the largest crowd of the season at Yankee Stadium.

Life will go on without Taty. While there are many concerns about goal scoring, the 2nd goal tonight that sealed all three points can help NYCFC fans sleep a little better.

Here it is:

It was a great team goal for New York City that gave fans a preview of what this team needs to do going forward. The whole team will need to step up if NYCFC are to replace his goal production. Much of that will fall to Hber, who rediscovered his goal-scoring form in his last few games. In his most recent four appearances in which he played more than ten minutes, Hber bagged five goals. If he can keep up that clinical touch, then it wont take all that much else to keep the goal production coming from NYCFC.

His goal also re-emphasized the idea that service into the box from the wing backs is crucially important for New York City. Part of what makes Malte Amundsen so important to this team is his ability to attack and cross balls into the box. Anton Tinnerholm is the king of providing this kind of service, but Tayvon Gray is doing a fine job for now by filling in on the right side.

The natural assumption is that Hber will reclaim his spot as the No 9, but Cushing provided an alternate idea postgame.

Hber is a ruthless number 9, but Im sure Talles would like a go up there, Cushing said postgame.

Talles Magnos made a couple of starts at the striker spot last season, but since then hes purely been a left winger with Taty and Hber filling the No 9 role. Playing Talles Magno at striker opens up this team to some interesting lineup decisions. This could lead to Gabriel Pereira or Thiago getting more opportunities to start as wingers instead of being reduced to substitute roles. Hber is still more than likely going to be the striker going forward, but look out for this when the schedule starts getting more cramped near the end of August.

For about 20-25 minutes of the second half, Miami controlled the game with possession. The good part of that for NYC was that the back line was not allowing Miami to create anything with all that possession. The defense held firm throughout that part of the game and did not allow Miami to truly threaten Sean Johnsons net.

Cushing lauded the back lines performance postgame.

Tayvon is an incredible one v one defender. Hes a good young player with potential and hes improving every week, Cushing said. I actually thought our two central defenders were incredible tonight. I thought by far our central defenders were our two star performers today.

Saturdays clean sheet makes it three in a row now for NYC. If this level of defending is sustained, then the attack can be given more time to figure life out without Taty.

At the end of the day, NYCFC got the job done and picked up three points at home against a weaker team on an emotional night. This now leads them into a tough stretch where five out of the next six games are on the road, with the only home game being a midweek game at Red Bull Arena. More of the same from a much-improved back line is going to be just as key as replacing Taty for NYC going forward.

Goals:

NYCFC, Maxi Moralez 12

NYCFC, Heber 75

Discipline:

NYCFC, Alfredo Morales, foul, yellow card, 14

Attendance: 23,277

Referee: Allen Chapman

Assistant Referees: Adam Garner, Gianni Facchini

Fourth Official: Luis Arroyo

VAR Referee: Ismail Elfath

Assistant VAR Referee: TJ Zablocki

Read the rest here:

Taty Castellanos plays his final game for NYCFC in 2-0 home win - Hudson River Blue

Kevork Djansezian/Getty Images

San Diego Padres shortstop Fernando Tatis Jr. said a move to center field is "not out of the question," per Ken Rosenthal of The Athletic.

"I like winning ballgames," Tatis said. "If it means we're going to win more ballgames like that, Ill do it that way."

The All-Star also said he has been shagging balls in the outfield.

Tatis has missed the entire 2022 season while recovering from a broken wrist, and he is not expected back until after the All-Star break. Ha-Seong Kim has filled in admirably at shortstop, which could push Tatis to the outfield.

Though he has primarily played shortstop in his professional career, Tatis made seven appearances at center field last season and 20 in right field.

After the season, Tatis told reporters his plan was to return to shortstop exclusively in 2022 and beyond.

"(A.J. Preller) signed a shortstop, and he's gonna have a shortstop," he said. "Thats the plan so far, and I'm not planning on moving for a very long time from there."

The 23-year-old has been inconsistent in the field, however, totaling minus-nine defensive runs saved over his three-year career, per FanGraphs. He was minus-six in the category last year alone.

Kim has 13 defensive runs saved over the past two years as a shortstop, including a plus-four mark this season, per FanGraphs.

Tatis is the far superior hitter and was an MVP candidate in each of the past two years. He finished last season hitting .282 with a .364 on-base percentage, 42 home runs and 25 stolen bases. His .975 OPS ranked fourth in the majors.

Kim has just a .223 average with four home runs with a .653 OPS this year.

The Padres could still fit both in the lineup with Tatis replacing the struggling Trent Grisham in center field, adding a huge bat to the offense without taking away Kim's strong defensive ability.

Tatis' apparent willingness to change positions could be a significant boost for San Diego's title hopes.

See the original post:

Padres' Fernando Tatis Jr.: Position Change to CF from SS 'Not out of the Question' - Bleacher Report

cstar55/E+ via Getty Images

Over the past month, energy and fertilizer stocks that have significantly outperformed the market YTD have come under significant pressure, despite having seemingly "cheap" valuations based on their normalized P/E.

CF Industries (NYSE:CF) stock was also hammered as the market continued to distribute the massive gains from its 2020 COVID bottom. In a May article on Mosaic (MOS), we cautioned investors that the market has been setting up the trap. We also highlighted similar price action structures in energy stocks such as Occidental (OXY) and Exxon (XOM), urging investors to take their profit (here and here).

In addition, the feedback that we received in our comments stream further corroborates our perspective that investors have gone gaga over such stocks, akin to highly optimistic sentiments (warning sign).

Our price action analysis also indicates that the market has been distributing CF stock since March, shortly after the start of the Russia-Ukraine conflict. It has been drawing in dip buyers astutely. Two significant bull traps, including a potent double top bull trap, emphasized the market's significant rejection of buying momentum. Coupled with its distribution phase, it highlighted the market's intention to force further selling, moving ahead.

Notably, CF stock is struggling at its near-term bottom after the recent sell-off. The market could continue to distribute further or force rapid selling soon (the duration is hard to predict). Therefore, we urge investors to consider layering out/cutting exposure soon, using potential rallies to cut more before it goes into the rapid liquidation phase.

CF price chart (monthly) (TradingView)

Poring into its monthly chart, we can glean the significant bull trap formed in March/April. Such parabolic moves are consistent with price action structures that indicate that the market had drawn buyers rapidly into the set-up. However, the market could use a distribution phase (duration is hard to predict) to draw in more dip buyers at the top before moving into the rapid liquidation subsequently.

We believe that CF stock is now mired in such a distribution phase that has taken place over the past three months.

CF price chart (weekly) (TradingView)

Zooming into its weekly chart, we can clearly observe its distribution phase. Saddled with two bull traps, including a potent double top (formed in April), we believe the stage has been for an eventual sharp decline.

Notably, the stock broke down its near-term support (which could turn into its near-term resistance if it does not retake). Our analysis suggests that CF stock could continue to distribute further along the current levels, allowing the market to draw in more dip buyers. However, we don't encourage investors to buy the dip here, given the potency of its double top bull trap.

Instead, we urge investors to consider layering out/cutting exposure and use potential rallies to sell even more positions.

CF revenue change % and adjusted EBIT change % consensus estimates (S&P Cap IQ)

The Street's consensus (generally bullish) is modeling for CF's revenue and adjusted EBIT to peak in FY22, before falling precipitously from FY23. Therefore, investors need to ask themselves why they should factor in another massive revenue increase if even the generally bullish Street analysts don't think so.

As a result, it would likely affect CF valuations as its free cash flow profitability would likely be impacted. Given the forward-looking perspective of the market, we believe the early warning sign from its double top bull trap is clear.

We rate CF stock as a Sell. As mentioned, it's at a near-term bottom, so a potentially short-term rally (dead cat bounce) could occur. But, we urge investors to use such potential rallies to reduce exposure.

CF's price action structure is looking increasingly perilous, and we believe a rapid liquidation could happen after the completion of its distribution phase. So, don't wait until then to sell.

Continued here:

CF Industries Stock: From Boom To Bust - Sell Into The Rallies (NYSE:CF) - Seeking Alpha

CENTRAL FALLS With 125 graduates crossing the stage at the Yip Soccer Field last Friday, Central Falls High School Principal Robert McCarthy commended the class of 2022 for recording-breaking academic achievements in spite of the obstacles faced during their high school career.

There are many popular phrases that apply to this class, like that does not kill us makes us stronger or the obstacle is the way, McCarthy said. These are so true for all of you because no matter the barrier, the adjustment, or the obstacle to your learning, you figured out a way to persevere and thrive in and out of the classroom.

Over cheers in the crowd, McCarthy said the graduating class submitted a higher number of successfully presented graduate portfolios than any preceding class in school history. He commended students who gave birth to three new honors societies that did not exist last year.

The Class of 2022 also helped start the first boys volleyball team, a cheerleading team and an e-sports team during the 2022 to 2023 school year. The seniors raised roughly $13,000 in eight months to fund their prom. The students succeeded in all this despite the hurdles of the COVID-19 pandemic, school closures, and virtual learning, McCarthy said.

... Youve touched all of us with your perseverance, exuberance, and flexibility, McCarthy said. We cannot wait to hear what you all accomplish when you leave high school.

He said he hopes to see students return to Central Falls as teachers, business owners, or community leader of the city because one way our schools get better is those of you who know CF, who are most connected to this community, come back and impact future generations and model what it means to be a Warrior.

Valedictorian Lyneth Mendoza reflected on the milestones of the students 12-year education, the first day of freshman year, and the day that completely changed our lives, March 13, 2020. From that day on, Mendoza said students bid farewell to what they considered a typical high school experience.

Some of us had to pick up extra shifts to make ends meet, while others needed to learn to balance taking care of family members and passing their classes, she said. These past two years have not been easy for any one of us.

While paths to get to graduation werent what students expected, they accomplished the goal. Mendoza said the Class of 2022s success has pushed against those who talked down on Central Falls, with students being accepted to some of the best schools in the country, and to the workforce.

Never let anyone else define what your life is going to be. You already have endured so much and have been so persistent throughout your high school career to prove you have what it takes to prosper, Mendoza said.

Taking the stage, salutatorian Darisel Velez said there were no perfect words to describe the phenomenon of time passing. Time, she said, stands no time match for the timelessness of the lessons we have learned and the lasting impact of people we have met.

With students having overcome personal and shared obstacles and battling busy workloads during their high school career, Velez said they became caught by the stressfulness of it all.

Somewhere along the way we became too busy, or maybe even too distracted to notice we were experiencing what our younger selves dreamed of accomplishing, Velez said. With the nationwide occurrence of tragic losses due to gun violence, we are reminded that we must protect our dreams

Velez said public fear is intolerable. After graduation, students may embark on their lives outside of the one-square-mile city of Central Falls, but as we celebrate our departure from high school we must know that with great accomplishment comes great responsibility.

City Council President Jessica Vega said students high school experience was filled with unique challenges that each graduate was bold enough to face. She said students set an example for students that follow, and have proven that they are capable of success in any path they choose.

From volunteering dozens of hours in community service, to trying new sports activities, to adapting throughout the difficult pandemic, to presenting your impressive senior portfolios, you have so much to be proud of, Vega said. ... Keep learning, keep growing, and stay involved in this community. Class of 2022, Central Falls will always be here for you

Student speaker and 2022 graduate Noelia Vazquez told classmates that the commencement ceremony was an opportunity for them to reflect on themselves, and to look into the eyes of their loved ones who believed in them and pushed them to accomplish this journey.

As graduates, we should recognize the accomplishments from the past, no matter the adversity, Vazquez said.

She recognized her own family, sharing the story of her brother who experienced a stroke at age 28, and who by the grace of God is still alive and who continues to encourage her. Vazquez thanked her teachers, specifically from the school science department, who helped her continue living the dream and reaching for a career in the medical field. She encouraged her peers to continue focusing on their own dreams, and to continue mastering yourself to make their loved ones proud and be a role model in life.

Supt. Stephanie Downey Toledo said some members of the graduating class may not know her well, but they mean a lot to her. She started with the district just as the Class of 2022 was entering high school as freshmen.

She shared the story of one student, when they were just a freshmen, who made an appointment to meet with her to tell her what needed to be improved across Central Falls schools.

She was right, Toledo said. And Im grateful to the parade of leaders in this class of 2022 that have continued to advocate ever since.

Whether students are heading to a four-year college, pursuing an associates degree, entering the military or the workforce, Toledo implored graduates to remain open as life-long learners.

While 125 students participated in last Fridays ceremony, McCarthy said an additional 20 students are expected to complete graduation requirements in time for an August graduation.

View original post here:

CF graduates to chart their own paths to success - Valley Breeze

NEWS STORY. 18/06/2022

VincentPoirierassessed game four of the final against Bara at the WiZink Center (Sunday, 6:00pm CEST): We know it's going to be a tough game, a real battle.Last night was incredible, it's the first time I've ever seen the WiZink like that. We need that same strength from the fans on Sunday. Every member of the team has stepped up to compete with opposition playing at a really high level and they understand what these games mean.I'm feeling good, yesterday was a huge game for us. We're showing our best defense of the season in every aspect. We know we're good offensively but everything starts with the defense. We have to keep working hard ahead of Sunday.Bara They're going to play hard, play tough, but we're ready to put on a good display and respond well with the energy of the fans behind us.We know we have to be highly focused and aggressive and compete for every ball. I want to win it and I'm going to give it my all".

View post:

Poirier: We need the strength of the fans" - Real Madrid CF

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that five scientific abstracts on the companys portfolio of cystic fibrosis (CF) medicines will be presented at the European Cystic Fibrosis Society's (ECFS) 45th European Cystic Fibrosis Conference held June 8-11, 2022, in Rotterdam, the Netherlands.

Vertex will present the first analysis of data collected in the U.S. CF Foundation Patient Registry (CFFPR) of over 16,000 people with CF treated with TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for an average of nine months. This first interim analysis of an ongoing five-year post-authorization study (abstract WS22.05) showed that real-world treatment with TRIKAFTA was associated with improved lung function and a 77% reduced risk of pulmonary exacerbations compared to pre-TRIKAFTA baseline, as well as an 87% lower risk of lung transplant and a 74% lower risk of death, compared to the historical 2019 U.S. CFFPR population. No new safety concerns were identified.

Vertex will also present data comparing the annual rate of lung function change in people with CF ages 12 years and older with two F508del mutations (F/F) or one F508del mutation and one minimal function mutation (F/MF) treated with TRIKAFTA in pivotal studies and an open-label extension study compared to propensity-score matched historical CFTR-modulator-untreated controls from the U.S. CFFPR (abstract WS22.04). Results show that TRIKAFTA demonstrated on average no decrease in ppFEV1 over a two-year period in this population, in contrast to declines seen in the matched controls. The analysis indicates that treatment with TRIKAFTA has a significant impact on the trajectory of CF lung disease.

Additionally, Vertex will present data from a long-term real-world study demonstrating that initiating KALYDECO (ivacaftor) early in life (ages 6-10 years) preserves lung function to a greater extent than if KALYDECO is initiated at an older age (abstract WS17.03). These results show the importance of early initiation of KALYDECO for eligible patients.

These long-term and real-world studies show the potentially transformative benefits of treatment with CFTR modulators and add to the substantial body of evidence supporting treatment as early in life as possible, said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer at Vertex. We continue to make rapid progress in developing medicines that treat the underlying cause of CF, and today, we are closer to our goal of developing highly effective therapies for all patients with CF than ever before.

Additional Presentations

In addition to the studies noted above, other Vertex presentations at the conference this year support the long-term and early use of CFTR modulators:

About Cystic Fibrosis

Cystic fibrosis (CF) is a rare, life-shortening genetic disease affecting more than 83,000 people globally. CF is a progressive, multi-organ disease that affects the lungs, liver, pancreas, GI tract, sinuses, sweat glands and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes one from each parent to have CF, and these mutations can be identified by a genetic test. While there are many different types of CFTR mutations that can cause the disease, the vast majority of people with CF have at least one F508del mutation. CFTR mutations lead to CF by causing the CFTR protein to be defective or by leading to a shortage or absence of CFTR protein at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus, chronic lung infections and progressive lung damage that eventually leads to death for many patients. The median age of death is in the early 30s.

About TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor)

In people with certain types of mutations in the CFTR gene, the CFTR protein is not processed or folded normally within the cell, and this can prevent the CFTR protein from reaching the cell surface and functioning properly. TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is an oral medicine designed to increase the quantity and function of the CFTR protein at the cell surface. Elexacaftor and tezacaftor work together to increase the amount of mature protein at the cell surface by binding to different sites on the CFTR protein. Ivacaftor, which is known as a CFTR potentiator, is designed to facilitate the ability of CFTR proteins to transport salt and water across the cell membrane. The combined actions of elexacaftor, tezacaftor and ivacaftor help hydrate and clear mucus from the airways.

TRIKAFTA is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one copy of the F508del mutation, or another mutation responsive to TRIKAFTA, in the CFTR gene. Patients should talk to their doctor to learn if they have an indicated CF gene mutation. It is not known if TRIKAFTA is safe and effective in children under 6 years of age.

Please see Important Safety Information below and [click here] for full U.S. Prescribing Information.

About KALYDECO (ivacaftor)

In people with certain types of mutations in the CFTR gene, the CFTR protein at the cell surface does not function properly. Known as a CFTR potentiator, ivacaftor is an oral medicine designed to facilitate the ability of CFTR proteins to transport salt and water across the cell membrane, which helps hydrate and clear mucus from the airways. KALYDECO (ivacaftor) was the first medicine to treat the underlying cause of cystic fibrosis (CF) in people with specific mutations in the CFTR gene.

KALYDECO is a prescription medicine used for the treatment of CF in patients aged 4 months and older who have at least one mutation in their CF gene that is responsive to KALYDECO. Patients should talk to their doctor to learn if they have an indicated CF gene mutation. It is not known if KALYDECO is safe and effective in children under 4 months of age.

Please see Important Safety Information below and [click here] for full U.S. Prescribing Information.

About ORKAMBI (lumacaftor/ivacaftor)

In people with two copies of the F508del mutation, the CFTR protein is not processed and trafficked normally within the cell, resulting in little to no CFTR protein at the cell surface.

ORKAMBI (lumacaftor/ivacaftor) is an oral medicine that is a combination of lumacaftor and ivacaftor. Lumacaftor is designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the F508del-CFTR protein. Ivacaftor, which is known as a CFTR potentiator, is designed to facilitate the ability of CFTR proteins to transport salt and water across the cell membrane. The combined actions of lumacaftor and ivacaftor help hydrate and clear mucus from the airways.

ORKAMBI is a prescription medicine used for the treatment of CF in patients age 2 years and older who have two copies of the F508del mutation (F508del/F508del) in their CFTR gene. ORKAMBI should only be used in these patients. It is not known if ORKAMBI is safe and effective in patients under 2 years of age.

Please see Important Safety Information below and [click here] for full U.S. Prescribing Information.

IMPORTANT SAFETY INFORMATION for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), KALYDECO (ivacaftor), and ORKAMBI (lumacaftor/ivacaftor)

Patients should not take KALYDECO or TRIKAFTA if they take certain medicines or herbal supplements, such as: the antibiotics rifampin or rifabutin; seizure medicines such as phenobarbital, carbamazepine, or phenytoin; or St. Johns wort.

Patients should not take ORKAMBI if they take certain medicines or herbal supplements, such as: the antibiotics rifampin or rifabutin; the seizure medicines phenobarbital, carbamazepine, or phenytoin; the sedatives and anti-anxiety medicines triazolam or midazolam; the immunosuppressant medicines cyclosporine, everolimus, sirolimus, or tacrolimus; or St. Johns wort.

Before taking KALYDECO, ORKAMBI, or TRIKAFTA patients should tell their doctor about all of their medical conditions, including if they: have or have had liver problems; have kidney problems; are pregnant or plan to become pregnant because it is not known if KALYDECO, ORKAMBI, or TRIKAFTA, will harm an unborn baby; or are breastfeeding or planning to breastfeed because it is not known if KALYDECO, ORKAMBI, or TRIKAFTA passes into breast milk. Before taking ORKAMBI, patients should tell their doctor if they have had an organ transplant, or if they are using a hormonal contraceptive including oral, injectable, transdermal, or implantable form as this should not be used as a method of birth control when taking ORKAMBI.

KALYDECO, ORKAMBI, or TRIKAFTA may affect the way other medicines work, and other medicines may affect how KALYDECO, ORKAMBI, or TRIKAFTA work. Therefore, the dose of KALYDECO, ORKAMBI, or TRIKAFTA may need to be adjusted when taken with certain medications. Patients should especially tell their doctor if they take antifungal medications such as ketoconazole, itraconazole, posaconazole, voriconazole, or fluconazole; or antibiotics such as telithromycin, clarithromycin, or erythromycin.

KALYDECO or TRIKAFTA can cause dizziness in some people who take it. Patients should not drive a car, use machinery, or do anything that needs them to be alert until they know how KALYDECO or TRIKAFTA affects them.

When taking ORKAMBI, patients should tell their doctor if they stop taking ORKAMBI for more than 1 week as their doctor may need to change the dose of ORKAMBI or other medicines the patient is taking.

Patients should avoid food or drink containing grapefruit while taking KALYDECO or TRIKAFTA.

KALYDECO, ORKAMBI, and TRIKAFTA can cause serious side effects, such as:

Liver damage and worsening of liver function in people taking TRIKAFTA with severe liver disease that can be serious and may require transplantation. Liver damage has also happened in people without liver disease.

High liver enzymes in the blood have been reported in patients receiving KALYDECO, ORKAMBI, or TRIKAFTA. The patient's doctor will do blood tests to check their liver before starting treatment with KALYDECO, ORKAMBI, or TRIKAFTA; every 3 months during the first year of treatment; and every year while on treatment. For patients who have had high liver enzymes in the past, the doctor may do blood tests to check the liver more often. Patients should call their doctor right away if they have any of the following symptoms of liver problems: pain or discomfort in the upper right stomach (abdominal) area; yellowing of their skin or the white part of their eyes; loss of appetite; nausea or vomiting; or dark, amber colored urine.

Worsening of liver function in people with severe liver disease taking ORKAMBI. The worsening of liver function can be serious or cause death. Talk to your doctor if you have been told you have liver disease as your doctor may need to adjust the dose of ORKAMBI.

Breathing problems such as shortness of breath or chest tightness in patients when starting ORKAMBI, especially in patients who have poor lung function. If a patient has poor lung function, their doctor may monitor them more closely when starting ORKAMBI.

An increase in blood pressure in some people receiving ORKAMBI. The patients doctor should monitor their blood pressure during treatment with ORKAMBI.

Abnormality of the eye lens (cataract) in some children and adolescents treated with KALYDECO, ORKAMBI, or TRIKAFTA. If the patient is a child or adolescent, their doctor should perform eye examinations before and during treatment with KALYDECO, ORKAMBI, or TRIKAFTA to look for cataracts.

The most common side effects of KALYDECO include headache; upper respiratory tract infection (common cold), which includes sore throat, nasal or sinus congestion, and runny nose; stomach (abdominal) pain; diarrhea; rash; nausea; and dizziness.

The most common side effects of ORKAMBI include breathing problems, such as shortness of breath and chest tightness; nausea; diarrhea; fatigue; increase in a certain blood enzyme called creatinine phosphokinase; rash; gas; common cold, including sore throat, stuffy or runny nose; flu or flu-like symptoms; and irregular, missed, or abnormal periods (menses) and increase in the amount of menstrual bleeding. Additional side effects seen in children include cough with sputum, stuffy nose, headache, stomach pain, and increase in sputum.

The most common side effects of TRIKAFTA include headache; diarrhea; upper respiratory tract infection (common cold), including stuffy and runny nose; stomach (abdominal) pain; inflamed sinuses; increase in liver enzymes; increase in a certain blood enzyme called creatine phosphokinase; rash; flu (influenza); and increase in blood bilirubin.

These are not all the possible side effects of KALYDECO, ORKAMBI, or TRIKAFTA. Please click product link to see the full U.S. Prescribing Information for KALYDECO, ORKAMBI, or TRIKAFTA.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) a rare, life-threatening genetic disease and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 12 consecutive years on Science magazine's Top Employers list and one of the 2021 Seramount (formerly Working Mother Media) 100 Best Companies. For company updates and to learn more about Vertex's history of innovation, visit http://www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements made by Dr. Bozic in this press release, statements regarding the potential benefits, safety and efficacy of our products, and our plans to present data about our portfolio of CF products at the ECFS European Cystic Fibrosis Conference, including an analysis of data from the ongoing five-year post-authorization safety study for TRIKAFTA, data comparing the annual rate of lung function change in certain individuals with CF and our assessment of the impact of such data, data regarding the early initiation of KALYDECO and our assessment of the impact of such data, and additional scientific presentations regarding our marketed CF products, including expectations regarding the abstracts that will be made available at the ECFS European Cystic Fibrosis Conference. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration, approval or further development of its compounds due to safety, efficacy or other reasons, risks related to approval and commercialization of our medicines, and other risks listed under the heading Risk Factors in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission (SEC) and available through the company's website at http://www.vrtx.com and on the SECs website at http://www.sec.gov. You should not place undue reliance on these statements or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

More here:

Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis...

Jayda Coleman can add another highlight to her reel as the Oklahoma center fielder made a sensational catch on Thursday during the Womens College World Series against Texas.

Coleman in the first inning kept he deficit at 2-0 when she reached over the outfield wall to bring back a would-be home run.

It stemmed the momentum that Texas built after Oklahoma delivered a huge blow to open the event on Wednesday with a 16-1 victory thanks to 6 home runs. Jocelyn Alo and Tiare Jennings each hit 2 home runs as top-seeded Oklahoma set a World Series record for home runs. Oklahoma is a victory away from successfully defending their Womens College World Series title.

OU coach Patty Gasso is no doubt impressed with Coleman the same way she was on Wednesday by Alo.

I guess I know her so well that I just think thats who she is. Gasso said. When she comes up, Im expecting her to hit a home run, probably like anybody else (laughter). Its ridiculous that Im thinking that way. But I see her at practice every day. I see what shes capable of. Its just so tough to beat her. Shes so strong.

Im spoiled, but I am not wowed by it because, like I said, I see it on a daily basis.

Continue reading here:

Jayda Coleman, Oklahoma CF, robs Texas of a home run at the wall - Saturday Down South

The Italian has been appointed as the new coach of Valencia CF, which will be his first experience of Spanish football.

There is a buzz in the air at Mestalla, with Valencia CF having confirmed the appointment of Gennaro Gattuso as their new head coach, replacing Jos Bordals. The Italian was one of the very best midfielders in the world during his career and has achieved several successes as a coach too, so will aim to jumpstart Valencia CF as the club seeks a return to European football.

Born in the south of Italy, Gattuso started his playing career at Perugia and then Scottish side Rangers, before signing with AC Milan and becoming a key cog in the Rossoneris winning machine during his 13 years there, between 1999 and 2012. He won several trophies in Milan, including two Champions League titles, while the hard-edged midfielder also lifted the World Cup with the Italian national team in 2006.

After finishing his playing career with Sion, Gattuso then took over as the Swiss clubs coach midway through the 2012/13 season. Although he had been studying to become a football coach for some time, it was a sudden start to his managerial career. Yet, Gattuso embraced the dugout and worked his way to the top of Italian football over the following decade, starting with stints at OFI Crete in Greece and Palermo and Pisa in Italy.

In 2017, he made a return to AC Milan to work in the Rossoneris youth academy and did such a good job that he was appointed as the head coach when Vincenzo Montella was sacked by AC Milan in November of 2017. He steadied the ship and remained in charge until the summer of 2019, before taking over at Napoli midway through the 2019/20 campaign and leading the Partenopei to a spectacular 2019/20 Coppa Italia victory.

Tenacious and technical football

Gattusos Napoli side played some spectacular football at times, with the midfielder shaking off the reputation hed earned as a player. As he himself has explained in a press conference: Theres no point in talking about Gattuso the player. We cant just talk about grit and heart. The aggression is still there, but Ive been through coaching courses. Ive studied and travelled. My coaching licence wasnt just handed to me as a present.

The Italian has even spoken about how much he admires the technical style of football that is more common in LaLiga Santander, even if he hated having to chase the ball when playing Spanish sides as a player. On this, Gattuso has said: The first few times I faced Spanish teams who played possession football, it did my head in. I used to go and press them on my own and theyd put me in the middle and pass the ball around. When I finished the game, I would say that in Italy we played another sport. I used to suffer in those games. I now see football differently to when I played. I like my teams to have possession and avoid taking risks.

This makes Gattuso such a special coach, as he can construct teams that play nice football when in possession but that also possess the necessary tenacity to win the ball back. That should go down very well at Mestalla.

Gattusos first experience in LaLiga Santander

This adventure with Valencia CF will be Gattusos first experience of LaLiga Santander, since he never played in Spain as a player and hasnt coached in the country yet either.

Even though there were no Italian players in LaLiga Santander in 2021/22, there were two coaches from the country in the form of Levante UDs Alessio Lisci and Real Madrids Carlo Ancelotti. Although Liscis Levante UD side were relegated, Valencia CFs appointment of Gattuso means that there will once again be two Italians in the dugouts of Spains top division.

When Gattuso faces Ancelotti, that will be a special occasion since the reigning Spanish and European champion coached the midfielder for so many years at AC Milan. In total, Gattuso played 323 times under Ancelotti and will hope to follow in his footsteps by achieving success in LaLiga Santander.

Read more from the original source:

Gennaro Gattuso brings tenacity and technique to the Valencia CF dugout - Yardbarker

Real Madrid, paced byTavares and Deck, took the most direct route to the final after victory in Vitoria secured a 3-0 semi-final series triumph againstBitci Baskonia.

Real Madrid is the first Endesa League finalist. Our team confirmed their superiority in the semi-final series against Bitci Baskonia after easing to victory in Game 3 to make it 3-0. Despite a number of players being ruled out and the absence of Pablo Laso, who has nowbeen dischargedafter suffering a heart attack, the side produced a great team display, with star performances from Tavares(23 points, 12 rebounds and a PIR of 36) andDeck(17, 8 and 27). Other standout performers wereHanga(18 points) andCauseur(14 and 7 rebounds) on a night when Madrid dominated from start to finish. The Whites will face the winners of the Barcelona v Joventut series in the final.Game 3 of the series got underway with a message of support for Laso from both teams and an ovation from the Buesa Arena faithful as Madrid lined up with Juan Nezas the only playmaker (Heurtel joined the rest of the players ruled out through injury). This didnt affect the guests as HangaandCauseurtook charge to inspire the team to an amazing first stanza, which featured five treys with a 62% success rate, domination on rebounds with Tavares starring and a low shot percentage for Baskonia. Within five minutes, the team had netted 18 points, eight in a row from the Frenchman and six from the Hungarian (14-25, min.10).Madrid ride Baskonia stormThe contest became tougher as the minutes ticked by as Baskonia displayed all of their aggression, which Madrid managed to counter, now on the inside, through Deckand Poirier to record a 12-point advantage at 19-31 (min.13). Baldwin IV and Fontecchio came to the hosts rescue and thanks to a fine run from the duo and a drop-off in shooting success from our team, they cut the lead to 32-35. It was at this point that Chus Mateoturned toTavares. Six straight points from the center (12 points and a PIR of 22 in his 13 minutes) got Madrid back on track and the guests headed in at the interval with a 36-41 lead.

Tavares re-establishes orderBaskonia was a triple away from levelling matters at 38-41 after the restart. This served as a wake-up call for Madrid, who wasted little time in producing a convincing response to break the hosts run. The madridistas tightened up in defense and Tavares was unstoppable in offense, both under the basket and in his shooting from 3-4 metres. The Cape Verde-born player, for whom this was already one of his best performances as a madridista, paced a 6-15 run in the next three minutes that eased the nerves amongst Chus Mateos charges, who went on to record a buffer of more than 15 points.Deck guarantees final berthHowever, Baskonia would again test the madridistas focus as Granger and Costello hauled their team back into contention to make it 64-69 on 33 after a technical foul on Hanga. Far from affecting the team and with the Buesa Arena fans willing the hosts on, the Whites put the result beyond doubt courtesy of another amazing run that was inspired by Deck. The Argentine was decisive and paced a 3-11 run in which Hanga was also heavily involved. The forward rounded off the series as he stood in for the absentees in the guard role. In two minutes between 34 and 36, our team tipped the match firmly in our favour to make it 66-81 and Baskonia simply had no answer. This win was dedicated to Laso as Real Madrid made it 10 final appearances in the last 11 seasons.BITCI BASKONIA v REAL MADRID STATISTICS

Read the rest here:

77-85: On to the league final - Real Madrid CF

Three Gator greats Brad Culpepper, Errict Rhett and Tim Tebow have been added to the 2023 ballot for induction into the College Football Hall of Fame. Florida has produced 13 Hall of Famers including Steve Spurrier, who was inducted both as a player and a coach.

Brad Culpepper, a former Gator defensive tackle, played for the Gators from 1988 to 1991 for both coach Galen Hall and Steve Spurrier. His accomplishments include First-Team All-SEC (1991), Consensus All-American (1991), and the Draddy Trophy (1991). He also helped his team win the SEC Championship in 1991.

Culpepper ranks sixth all-time at Florida with 47.5 career tackles for loss, a school record among defensive linemen. This is Culpeppers second nomination for the College Football HOF.

Congrats to Gator Greats, Brad Culpepper, @ErrictRhett1 and @TimTebow on being named to the 2023 ballot for induction into the @cfbhall! ?#GoGators | #GatorMade

— Florida Gators Football (@GatorsFB) June 6, 2022

Errict Rhett, former running back for the Gators, was the first player in FBS history to rush for more than 4,100 yards and catch more than 140 passes in a career.

Rhett was a three-time All-SEC selection, made First Team All-American, and was the 1994 Sugar Bowl MVP. He scored 34 touchdowns in his four-year career and lead the Gators in rushing for all four seasons of his college career. He finished off his Gator career with a three touchdown performance in the 1994 Sugar Bowl, leading to his MVP honor.

Former Gator quarterback Tim Tebow is considered one of the most legendary quarterbacks in the history of Gator football. Tebow was the first sophomore in college football history to win the Heisman Trophy. He has also won countless awards: the NFF Campbell Trophy (2009), the Maxwell Award (2007, 2008), the Davey OBrien Award (2007), and First Team All-American (2007).

Tebow was a three-time SEC Offensive Player of the Year. The former Gator set 28 school records during his career. His most memorable accomplishment was leading his team to a pair of national championships in 2006 and 2008.

The 2023 class is set to be officially inducted during the 65th National Football Foundation Annual Awards Dinner on December 5, 2023. Theyll hold a permanent spot in the Chick-fil-A College Football Hall of Fame in Atlanta.

They will be honored at their respective schools with an NFF Hall of Fame On-Campus Salute during the 2023 season.

See the article here:

Gator Greats On CF Hall of Fame Ballot - ESPN 98.1 FM - 850 AM WRUF - WRUF